Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
about
Smoldering multiple myeloma requiring treatment: time for a new definition?Designing a broad-spectrum integrative approach for cancer prevention and treatment.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Curcumin and cancer: barriers to obtaining a health claim.How I treat smoldering multiple myeloma.The multifaceted role of curcumin in cancer prevention and treatment.Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaCurcumin in various cancers.Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.The road to cure in multiple myeloma starts with smoldering disease.Epigenetic targets in cancer and aging: dietary and therapeutic interventions.Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases.Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies.Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic LeuA gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.Complementary or alternative medicine in cancer care-myths and realities.Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges.MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.Long-term stabilisation of myeloma with curcumin.B-Cell Disorders and Curcumin.Timing of treatment of smoldering myeloma: delay until progression
P2860
Q26996579-C9E63DAD-D6C9-4605-B6AA-369D56B841FAQ30736359-1A7E3850-DCC1-4C10-B468-80D71EC08F85Q34316559-C9ACBC5F-48FE-475A-B627-4A1C723624BFQ34478532-EF987E94-900C-4BFF-8F55-4E8EC667C4BCQ34580094-51CB9ADB-4C6F-403C-804D-4DAD8CA7DEA8Q34667865-85B3D27F-8697-4041-A7AF-4F07DBCF9095Q35833408-A7454B59-1F6A-4236-99F2-655EDA68DF07Q36777247-EF86A170-266B-44B4-85CC-D274DDA138ABQ37171994-BB2694DF-6287-4B01-B9AC-27BF8564C5D0Q38072890-0CECBD1B-B838-4BF1-8B9F-251A4D87C3B7Q38190593-9B5B17F3-769F-4381-98A2-891756D7591DQ38199088-580D5E06-C39F-46E8-9A58-AE35B1F56426Q38199534-008B7B0A-4556-4BE4-BD42-A48EBF56C9EAQ38494968-D2881EB2-C5BA-4B69-8901-1ADA3E4AEF9DQ38669233-073DEB85-4A13-47AF-93BB-902430C4DECCQ38740697-19998A0B-1341-4E46-A2FA-9B7CE49141C0Q38927737-E8B16FA2-5A8F-4AA0-968C-421F1E753298Q38957154-1AEB9D00-62E9-42B6-A440-C34F68E5677FQ39044440-0CB7A556-80F1-4CA5-AF33-F336E72F6D24Q40684364-D0528A8E-2B9E-4F08-9204-AD461F9B3718Q41091865-71148E22-0759-4F34-A9B2-FBDE711D5C56Q45749220-7319FCFB-0E21-48CA-89AF-A6C111BB9286Q47241744-79424BE7-D87D-4BE8-A5DE-96382E813F0BQ47702288-2AF70D32-980F-4890-89BA-5029D1B5D4D0Q49736620-4F9C4B8E-7A2F-4FD4-A393-462D66B46C60Q49773570-293CF43A-FB26-4C52-B677-1457CBC37E24Q59137902-BAFF6766-A892-499A-8C36-0C8FC1ECBDD8
P2860
Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@ast
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@en
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@nl
type
label
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@ast
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@en
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@nl
prefLabel
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@ast
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@en
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@nl
P2093
P2860
P356
P1476
Monoclonal gammopathy of undet ...... open-label 8g extension study.
@en
P2093
Arumugam Manoharan
Rajeev Ramakrishna
Terrence H Diamond
Terry Golombick
P2860
P304
P356
10.1002/AJH.23159
P577
2012-04-04T00:00:00Z